Physicochemical Profiling of Baicalin Along with the Development and Characterization of Cyclodextrin Inclusion Complexes

Géza Jakab, Dóra Bogdán, Károly Mazák, Ruth Deme, Zoltán Mucsi, István M. Mándity, Béla Noszál, Nikolett Kállai‐Szabó, István Antal

AAPS PharmSciTech · 2019 · 65 citations · 28 references

DOIFull text

Open access

Concepts

Abstract

Abstract Baicalin is a flavone glycoside extracted from Scutellaria baicalensis , a traditional Chinese herbal medicine. Numerous pharmacological effects of baicalin were reported ( e.g. antioxidant, anxiolytic); nevertheless, the most important physicochemical properties influencing the pharmacokinetic behaviour and the concomitant oral bioavailability have not yet been described in a comprehensive study. The aim of this project was to characterize the acid-base, lipophilicity, biorelevant solubility and permeability properties of the drug substance and providing scientific data to support the dosage form design. Another important objective was the comparative evaluation of six various baicalin-cyclodextrin (CD) inclusion complexes along with the creation of a suitable Drug Delivery System (DDS) for this BCS IV drug. Biorelevant profiling was carried out by NMR-pH titrations, saturation shake-flask and distribution coefficients (log P ) measurements, while CD inclusion studies were fulfilled by experimental methods (phase solubility, 1 H/ 13 C NMR, 2D ROESY) and computational approaches. Due to low aqueous solubility (67.03 ± 1.60 μg/ml) and low permeability ( P app = 0.037 × 10 −6 cm/s), baicalin is classified as BCS IV. The γ-CD complexation significantly increased the solubility of baicalin (~ 5 times). The most promoted chemical shift change occurred in baicalin-γ-CD complex. Computational studies showed disparate binding pattern for baicalin in case of β- and γ-CD; furthermore, the calculated complexation energy was − 162.4 kJ mol −1 for β-CD, while it was significantly stronger for γ-CD (− 181.5 kJ mol −1 ). The physicochemical and structural information of baicalin and its CD complexes introduced herein can create molecular basis for a promising DDS with enhanced bioavailability containing a bioactive phytopharmacon.

References

28